Croda International Plc (LSE:CRDA) agreed to acquire Solus Biotech Co., Ltd. from Solus Advanced Materials Co., Ltd. (KOSE:A336370) for KRW 350 billion on February 3, 2023. The acquisition is subject to regulatory approval. Lazard & Co., Limited acted as financial advisor to Croda International Plc (LSE:CRDA).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17,040 KRW | -4.00% |
|
-6.73% | +28.60% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.60% | 912M | |
+9.79% | 105B | |
+4.36% | 20.68B | |
-12.70% | 18.48B | |
-12.24% | 16.17B | |
+10.26% | 15.5B | |
+15.81% | 12.65B | |
+2.63% | 12.56B | |
+12.89% | 8.41B | |
-0.98% | 8.12B |
- Stock Market
- Equities
- A336370 Stock
- News Solus Advanced Materials Co., Ltd.
- Croda International Plc agreed to acquire Solus Biotech Co., Ltd. from Solus Advanced Materials Co., Ltd. for KRW350 billion.